Survival in patients with neuroendocrine tumors of the colon, rectum and small intestine

Senapathi, Sri H.; Keller, Hilary R.; Morada, Anthony; Bertsch, David; Cagir, Burt

doi:10.1016/j.amjsurg.2022.09.053

Cited by 8 publications

(10 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median overall survival in our SI-NET patient cohort was 10.1 years, which was comparable to survival in a national cohort from Iceland (9.1 years) [ 9 ] and referral centre cohort from Norway (9.3 years) [ 16 ] but considerably higher than that reported in a recent analysis of SEER data from the United States of America (52 months) [ 15 ]. Several factors were associated with overall survival.…”

Section: Discussionsupporting

confidence: 74%

“…Primary SI-NETs metastasize to mesenteric lymph nodes early in the disease course, and many patients also have liver metastases at the time of diagnosis [ 10 , 11 ]. Still, SI-NETs have an advantageous survival relative to many other cancers, with 5-year overall survival rates in the range of 61–77% [ 12 , 13 , 14 , 15 , 16 , 17 ]. Patients with localized, regional disease and some patients with distant metastases are considered for surgery with curative intent [ 18 ], while treatment with somatostatin analogues [ 19 , 20 ] and 177 Lu-DOTATATE [ 21 ] improve survival in patients with metastatic disease in randomized controlled trials.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Survival Trends in Patients with Small Intestinal Neuroendocrine Tumours—A Cohort Study in Central Norway

Folkestad

Hauso

Mjønes

et al. 2023

Cancers

View full text Add to dashboard Cite

Improved surgical resection and oncological treatment, or an earlier diagnosis may increase survival in small intestinal neuroendocrine tumours (SI-NETs), but only few studies have examined survival trends. We aimed to examine the trend in overall survival and associated factors in SI-NET patients. All patients with SI-NETs at a regional hospital from June 2005 to December 2021 (n = 242) were identified, and the cohort was divided in half, constituting a first period (until November 2012) and a second period (from November 2012). Disease and treatment characteristics, including European Neuroendocrine Tumour Society (ENETS) stage, surgery, oncological treatment and survival, were recorded. The majority (n = 205 (84.7%)) were treated surgically and surgery was considered curative in 137 (66.8%) patients. Median survival was longer in the second period (9.0 years 95% CI 6.4–11.7 in the first period vs. median not reached in the second period, p = 0.014), with 5-year survival rates of 63.5% and 83.5%, respectively. ENETS stage and oncological treatment did not differ between the periods, but factors associated with surgical quality, such as lymph node harvest and resection of multiple SI-NETs, were significantly higher in the second period. Age, ENETS stage, time period and tumour resection were independently associated with survival in a multivariate analysis.

show abstract

Section: Discussionsupporting

confidence: 74%

Section: Introductionmentioning

confidence: 99%

Survival Trends in Patients with Small Intestinal Neuroendocrine Tumours—A Cohort Study in Central Norway

Folkestad

Hauso

Mjønes

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Sorbye et al demonstrated that patients with primary colon tumors had significantly shorter median survival compared with other primary tumors [ 25 ]. Regarding independent factors associate with decreased mortality, a previous study also reported GI NEC from the small intestine as presenting better 5-year OS (68.2%) compared NECs of the rectum or colon ( p < 0.001) [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

Predictive Nomogram and Propensity Score Matching in Neuroendocrine Carcinoma of the Tubular Gastrointestinal Tract: A US Population-Based Clinical Outcome Study

Yasinzai,

Khan,

Chandasir

et al. 2024

Cancers

View full text Add to dashboard Cite

Background: Neuroendocrine carcinomas (NECs) of the tubular gastrointestinal tract (GI-NECs) are rare and associated with worse clinical outcomes. This population-based study aims to highlight key demographics, clinicopathological factors, and survival outcomes in the US population. Methods: Data from 10,387 patients with GI-NECs were extracted from the Surveillance, Epidemiology, and End Result (SEER) database from 2000 to 2020. Results: Most patients were >40 years old at the time of presentation with a median age of 63 years old, with almost equal ethnic distribution per US population data. The most common primary tumor site was the small intestine (33.6%). The metastatic spread was localized in 34.8%, regional in 27.8%, and distant in 37.3% of cases, and the liver was the most common site of metastasis (19.9%) in known cases of metastases. Most NEC patients underwent surgery, presenting the highest 5-year overall survival of 73.2% with a 95% confidence interval (CI) (95% CI 72.0–74.4%), while chemotherapy alone had the lowest 5-year survival of 8.0% (95% CI 6.4–10.0%). Compared to men, women had a superior 5-year survival rate of 59.0% (95% CI 57.6–60.5%). On multivariate analysis, age > 65 (HR 2.49, 95% CI 2.36–2.54%, p ≤ 0.001), distant metastasis (HR 2.57, 95% CI 2.52–2.62%, p ≤ 0.001), tumor size > 4 mm (HR 1.98, 95%, CI 1.70–2.31%, p ≤ 0.001), esophageal (HR 1.49, 95% CI 0.86–2.58%, p ≤ 0.001), transverse colon (HR 1.95, 95% CI 1.15–3.33%, p ≤ 0.01), descending colon (HR 2.12, 95% CI 1.12, 3.97%, p = 0.02) anorectal sites, and liver or lung metastases were associated with worse survival. Surgical intervention and tumors located in the small intestine or appendix showed a better prognosis. Conclusion: GI-NECs are a group of rare malignancies associated with a poor prognosis. Therefore, epidemiological studies analyzing national databases may be the best alternative to have a more comprehensive understanding of this condition, assess the impact of current practices, and generate prognosis tools.

show abstract

“…Unusual presentation of a neuroendocrine tumor in the ileostomy specimen after rectal cancer treatment: a case report presentation is usually why these tumors are discovered at a late stage, sometimes in association with symptomatic metastatic disease (2). At the time of diagnosis, 12% of small intestinal neuroendocrine tumors under 1 cm in size are associated with positive lymph nodes.…”

Section: Case Reportmentioning

confidence: 99%

Unusual presentation of a neuroendocrine tumor in the ileostomy specimen after rectal cancer treatment: a case report

Bustamante-Lopez¹,

Allawi²,

Yu³

et al. 2023

Transl Cancer Res

View full text Add to dashboard Cite

Background: Neuroendocrine tumors of the small intestine are uncommon, but at the same time they are the most frequent subtype of neuroendocrine tumor in the gastrointestinal system. They originate from enterochromaffin cells, which are involved in the creation of serotonin. This asymptomatic characteristic in the initial presentation is usually why these tumors are discovered at a late stage, sometimes in association with symptomatic metastatic disease.Case Description: We present a case-report of a 52-year-old gentleman with a suggestive family history of hereditary cancer syndrome (mother with lung cancer and maternal uncle with colon cancer at the age of 40 years old). The patient was diagnosed with rectal cancer and he received neoadjuvant chemotherapy with short-course radiotherapy followed by a robotic low anterior resection with diverting loop ileostomy.Following closure of his ileostomy, the pathology report of the ileostomy resection specimen showed a 1.1 cm neuroendocrine tumor with negative margins.Conclusions: This extraordinary unusual presentation could be very fortuity for the patient, who in every other opportunity just found this neuroendocrine tumor after advanced or maybe metastatic diseases.

show abstract

Survival in patients with neuroendocrine tumors of the colon, rectum and small intestine

Cited by 8 publications

References 41 publications

Survival Trends in Patients with Small Intestinal Neuroendocrine Tumours—A Cohort Study in Central Norway

Survival Trends in Patients with Small Intestinal Neuroendocrine Tumours—A Cohort Study in Central Norway

Predictive Nomogram and Propensity Score Matching in Neuroendocrine Carcinoma of the Tubular Gastrointestinal Tract: A US Population-Based Clinical Outcome Study

Unusual presentation of a neuroendocrine tumor in the ileostomy specimen after rectal cancer treatment: a case report

Contact Info

Product

Resources

About